B7‐H3, a newly discovered member of the B7 family, is often overexpressed in a variety of types of human cancers, and its overexpression is closely correlated with survival, prognosis, or grade of tumor.20 Moreover, B7‐H3 has been demonstrated to mediate T‐cell proliferation and interferon‐γ production.34 Targeting B7‐H3 with monoclonal antibodies for the advanced‐stage central nervous system cancer in children has achieved effective results,20 making B7‐H3 a promising therapeutic target for cancer. This evidence concerns the gene CD276 and central nervous system cancer.